Single-Port Robotic Cytoreductive Surgery for Colon Cancer Peritoneal Recurrence with the da Vinci SP.

Ann Surg OncolJun 19, 2026 (epub)
Case ReportGeneral SurgeryOncology (Medical)Open access

Hoyeon Kwon, Soo Yeun Park

✦ AI-curated · Sources linked

Case in brief

A 61-year-old female with colon cancer developed ovarian and peritoneal metastases 14 months post-laparoscopic right hemicolectomy. After seven cycles of neoadjuvant chemotherapy, she underwent cytoreductive surgery (CRS) using the da Vinci SP robotic system. The procedure, which included multiple resections and hyperthermic intraperitoneal chemotherapy, was completed successfully with complete cytoreduction. The patient was discharged on day 9 without complications and has remained recurrence-free for over 6 months.

Diagnostic / clinical pearl

The use of single-port robotic surgery for cytoreductive procedures in selected patients with peritoneal metastases may enhance recovery while minimizing abdominal wall trauma.

Source

PubMed · PMID 42319590Free full text on PubMed Central

Published in Ann Surg Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.